Losartan and mirabegron did not change the SERCA expression and pPLN/PLN expressions in CKD, suggesting that these proteins did not play a crucial role in the effects causing improved diastolic function in the losartan and mirabegron-treated groups. This evidence concerns the gene PLN and chronic kidney disease.